Idiopathic Membranous Nephropathy (IMN) Emerging Therapy and TPP Insights

Thelansis’s “Idiopathic Membranous Nephropathy (IMN) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Idiopathic Membranous Nephropathy (IMN) Overview

Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome in adults, characterised by autoantibody-mediated subepithelial immune complex deposition along the glomerular basement membrane, disrupting podocyte integrity and glomerular filtration barrier function. Anti-PLA2R antibodies — present in approximately 70-80% of cases — represent the dominant pathogenic autoantibody, with anti-THSD7A and emerging novel antigenic targets accounting for remaining cases. Patients present with insidious nephrotic syndrome — heavy proteinuria, hypoalbuminaemia, peripheral oedema, and hyperlipidaemia — carrying significant thromboembolic risk, particularly renal vein thrombosis, and progressive chronic kidney disease potential. Diagnosis integrates renal biopsy demonstrating pathognomonic subepithelial deposits on electron microscopy alongside anti-PLA2R titre quantification, serving dual diagnostic and disease activity monitoring roles. The “rule of thirds” guides initial management — approximately one-third remit spontaneously — justifying conservative therapy with optimised RAAS blockade, lipid management, and anticoagulation before immunosuppression. Rituximab, targeting CD20-positive B-cells to deplete autoantibody-producing clones, has supplanted traditional cyclophosphamide-based Ponticelli regimens and calcineurin inhibitors as the preferred first-line immunosuppressive strategy, offering favourable efficacy and tolerability. Obinutuzumab represents an emerging anti-CD20 option in rituximab-refractory disease. Prognosis is variable; serial proteinuria and anti-PLA2R titre monitoring alongside sustained nephrology surveillance underpin long-term patient-centred management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)